AKT1 and leukemia: Given the pivotal roles of these pathways, developing and testing dual inhibitors targeting both the Hh and PI3K/Akt/mTOR pathways offers a promising future strategy for overcoming therapy resistance and improving treatment outcomes in leukemia and other cancers.